Slide 1: Poised to Revolutionize the Carotid Intervention Market
Poised to Revolutionize the Carotid Intervention Market March 2026
Slide 2: Disclaimers
Disclaimers Forward-looking statements This presentation contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future f
Slide 3: Developer of CGuard Prime Carotid Stent Platform
Developer of CGuard® Prime Carotid Stent Platform Dedicated to advancing the prevention of stroke and treatment of carotid artery disease MicroNet Mesh-Covered Protection SmartFit Technology 3
Slide 4: Executive Leadership Team
Executive Leadership Team Deep industry experience and subject matter expertise Marvin Slosman Shane Gleason Mike Lawless Chief Executive Officer Chief Commercial Officer Chief Financial Officer • 30+ years of medical device • 20+ years of cardiovascular medical • 20+ years of financial management,
Slide 5: Carotid Stenting Revolution Has Arrived
Carotid Stenting Revolution Has Arrived MicroNetTM covered CGuard® stent platform could become the new gold standard CEREBRAL CORONARY THORACIC/ABDOMINAL PERIPHERAL CAROTID ARTERY CAROTID ARTERY ANEURYSMS ARTERY DISEASE AORTIC ANEURYSMS ARTERIAL DISEASE DISEASE DISEASE 12% CAGR5 45%Endo 77% Endo2 65
Slide 6: $8B Global Market Potential
$8B Global Market Potential Carotid remains significantly underpenetrated Only 14% of diagnosed patients are treated annually 86% Untreated ~400,000 ~2.4M (1) Annual Global Patients Diagnosed With High Grade Carotid Stenosis (HGCS) Annual Global Procedures But Left Untreated 160,000+ Current Annual
Slide 7: Carotid Revascularization at an Inflection Point
Carotid Revascularization at an Inflection Point Evidence. Policy. Platform. Team. ENDOVASCULAR PLATFORM ORGANIZATIONAL MARKET SHIFT ADVANTAGE READINESS CGuard® Carotid Stent Platform Unmatched Clinical Evidence CMS Coverage Expanded Proprietary MicroNet Technology Short and Long-Term Results Standa
Slide 8: Long-Term Stent Performance is the Cornerstone of Our Business
Long-Term Stent Performance is the Cornerstone of Our Business Benefits are independent of access method We are positioned to CGuard Prime CAS Tandem capitalize on the ongoing Stroke Transfemoral/ paradigm shift toward a Transradial “stent first” approach and away from surgery CGuard® Prime Tandem T
Slide 9: Market Trends
Market Trends CAS/TCAR continues to gain over CEA US Market Size CEA CAS/TCAR $987M 30,000 $836M $296 25,000 20,000 $460 $277 15,000 10,000 CREST-2 $150 $207 CAS coverage publication expansion 5,000TCAR coverage $113 expansion $207 $113 - 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 2025 2030 202
Slide 10: A Picture is Worth a Thousand Words
A Picture is Worth a Thousand Words… VS 90% occlusion CGuard® Stent Surgical Endarterectomy Stenting 10
Slide 11: Stent Design Comparison
Stent Design Comparison Conventional carotid stents vs CGuard® Prime dual layer design Conventional Carotid Stent CGuard Prime Dual Layer Design ▪ CGuard Prime is designed to prevent embolization by securing carotid plaque behind its MicroNet mesh, preventing prolapse through the stent struts while
Slide 12: Unmatched Foundational Data and Evidence
Unmatched Foundational Data and Evidence 12
Slide 13: C-GUARDIANS: 30-Day Safety Outcomes
C-GUARDIANS: 30-Day Safety Outcomes 30-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials CGUARDIANS 30-day outcomes 30-day DSMI (multiple FDA trials) Intention to Treat Per Protocol1,2 8.30% 30-day DSMI 0.95% (3) 0.63% (2) 5.80% 5.40% 5.20% 5.10% 4.80% Death 0.32% (1) 0.0% (0) 3.50%
Slide 14: C-GUARDIANS: 1 Year Outcomes
C-GUARDIANS: 1 Year Outcomes 365-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials CGUARDIANS 365-day 365-day (multiple FDA trials) Intention to Treat Per Protocol1,2 12.20% 9.60% Primary Endpoint: 30-day 8.90% Death, Stroke, or MI + 1.93% (6) 1.70% (5) Ipsilateral Stroke between 7.
Slide 15: OUS Clinical Data Supporting CGuard Periprocedural Safety
OUS Clinical Data Supporting CGuard® Periprocedural Safety CGuard commercially available in Europe since 2015 (CE Mark) Study Year N DS 30-Day % (n) DSMI 30-Day % (n) CARENET 2015 30 0.0%(0) 0.0%(0) PARADIGM 2016 101 0.0%(0) 0.0%(0) CASANA 2017 82 1.22%(1) 1.22%(1) WISSGOTT I 2017 30 0.0%(0) 0.0%(0)
Slide 16: CARMEN Meta-Analysis (112 Studies, 68K Patients)
CARMEN Meta-Analysis (112 Studies, 68K Patients)1 30-day and 12-month event rates by stent type (random-effect model) Terumo Gore Event FGS SGS RoadSaver/ (not marketed) CGuard • Improvements from second- Casper generation stents (SGS) 30-day Stroke [%] 3.01 0.60 0.50 2.89 0.54 relative to first-gen
Slide 17: CREST-2 Outcomes Highlight CAS
CREST-2 Outcomes Highlight CAS • Stroke and death (S/D) out to 4-years Any Perioperative Stroke or Death Plus Ipsilateral Stroke Thereafter up to 4 Years was 6.0% for medical therapy and 2.8% when CAS was added • Absolute difference of 3.2% favoring CAS was significant Med Alone • Only 31 people wit
Slide 18: TCAR
TCAR INSPIREM9
Slide 19: Transcarotid Arterial Revascularization (TCAR): Direct Carotid Access with Reverse Flow
Transcarotid Arterial Revascularization (TCAR): Direct Carotid Access with Reverse Flow InspireMD Combines SwitchGuard NPS with Best-in-Class CGuard® Implant 1. Transient flow reversal combined with sustained embolic prevention in transcervical revascularization of symptomatic and highly-emboligenic
Slide 20: Commercial and Corporate
Commercial and Corporate INSPIREM9
Slide 21: CMS Final National Coverage Determination, October 11, 2023
CMS Final National Coverage Determination, October 11, 2023 The final decision memorandum, which affects NCD 20.7 sections B4 and D, revises Medicare coverage for Percutaneous Transluminal Angioplasty (PTA) of the carotid arteries concurrent with stenting by: 1 Expanding coverage to individuals prev
Slide 22: Roadmap / Milestones
Roadmap / Milestones Key Value Drivers 2026 2027 ✓ CGUARDIANS II Enrollment Completion & PMA-S Submission CGuard Prime® indicated stent for TCAR Potential SwitchGuard NPS Clearance / Launch (Full TCAR Tool Kit) Potential CGuard Prime TCAR Approval CGuard Prime indicated stent with SwitchGaurd CGuard
Slide 23: Commercial Footprint
Commercial Footprint Current Markets • Active selling in more than 30 countries • Over 70,000 systems sold • Average CAS market share of 25% OUS 23
Slide 24: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio Proprietary platform technology supported by IP Patent Rights Issued Pending USA 20 6 Rest of World 51 21 InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products IP Counsel: Kligler and Associates, P.A
Slide 25: Transformational July 2025 PIPE and May 2023 Financing Up To $153.7 Million
Transformational July 2025 PIPE and May 2023 Financing Up To $153.7 Million To advance the company towards successful U.S. commercialization and path to profitability Strong validation from leading July 2025 PIPE Financing of $40.1 million fundamental healthcare investors, with additional participat
Slide 26: Scientific Advisory Board (Multidisciplinary KOLs)
Scientific Advisory Board (Multidisciplinary KOLs) Sean Lyden, M.D. Chris Metzger, M.D. Kenneth Rosenfield, M.D. Adnan H. Siddiqui, M.D., Ph.D. Vascular Surgeon Medical Director Interventional Cardiologist Professor, Vice Chairman of Cardiologist the Department of Neurosurgery 26
Slide 27: Accelerating Growth Driven By Ongoing U.S. Commercial Launch & Product Innovation Roadmap
Accelerating Growth Driven By Ongoing U.S. Commercial Launch & Product Innovation Roadmap Quarterly Revenue ($M) Annual Revenue ($M) +56% 1 +62% $14.0 $3.1 +39% $2.5 +28% +2% $9.0 +1% +13% $1.8 +20% $7.0 $1.5 $6.2 Q1'25 Q2'25 Q3'25 Q4'25 2023 2024 2025 2026E U.S. Commercial Launch in July 1) FY2026E
Slide 28: Nasdaq: NSPR
NASDAQ Nasdaq: =NSPR NSPR